681 related articles for article (PubMed ID: 25890222)
1. Genomic profiling guides the choice of molecular targeted therapy of pancreatic cancer.
Frank TS; Sun X; Zhang Y; Yang J; Fisher WE; Gingras MC; Li M
Cancer Lett; 2015 Jul; 363(1):1-6. PubMed ID: 25890222
[TBL] [Abstract][Full Text] [Related]
2. Targeting dynamics of subclones of GI, liver and pancreatic cancers.
Ziogas DE; Glantzounis G; Liakakos T; Roukos DH
Expert Rev Gastroenterol Hepatol; 2016 Jul; 10(7):773-6. PubMed ID: 27143511
[No Abstract] [Full Text] [Related]
3. Molecular targets for the treatment of pancreatic cancer: Clinical and experimental studies.
Matsuoka T; Yashiro M
World J Gastroenterol; 2016 Jan; 22(2):776-89. PubMed ID: 26811624
[TBL] [Abstract][Full Text] [Related]
4. Molecular classification as prognostic factor and guide for treatment decision of pancreatic cancer.
Birnbaum DJ; Bertucci F; Finetti P; Birnbaum D; Mamessier E
Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):248-255. PubMed ID: 29499330
[TBL] [Abstract][Full Text] [Related]
5. Genomic profiling of brain metastases: current knowledge and new frontiers.
Neagu MR; Gill CM; Batchelor TT; Brastianos PK
Chin Clin Oncol; 2015 Jun; 4(2):22. PubMed ID: 26112808
[TBL] [Abstract][Full Text] [Related]
6. Speeding towards individualized treatment for pancreatic cancer by taking an alternative road.
Iovanna J; Dusetti N
Cancer Lett; 2017 Dec; 410():63-67. PubMed ID: 28947138
[TBL] [Abstract][Full Text] [Related]
7. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
Le Tourneau C; Delord JP; Gonçalves A; Gavoille C; Dubot C; Isambert N; Campone M; Trédan O; Massiani MA; Mauborgne C; Armanet S; Servant N; Bièche I; Bernard V; Gentien D; Jezequel P; Attignon V; Boyault S; Vincent-Salomon A; Servois V; Sablin MP; Kamal M; Paoletti X;
Lancet Oncol; 2015 Oct; 16(13):1324-34. PubMed ID: 26342236
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic Implications of Molecular Subtyping for Pancreatic Cancer.
Pishvaian MJ; Brody JR
Oncology (Williston Park); 2017 Mar; 31(3):159-66, 168. PubMed ID: 28299752
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive molecular tumor profiling in radiation oncology: How it could be used for precision medicine.
Eke I; Makinde AY; Aryankalayil MJ; Ahmed MM; Coleman CN
Cancer Lett; 2016 Nov; 382(1):118-126. PubMed ID: 26828133
[TBL] [Abstract][Full Text] [Related]
10. Advances in Molecular Pathology and Treatment of Periampullary Cancers.
Chandrasegaram MD; Chen JW; Price TJ; Zalcberg J; Sjoquist K; Merrett ND
Pancreas; 2016 Jan; 45(1):32-9. PubMed ID: 26348463
[TBL] [Abstract][Full Text] [Related]
11. Molecular profiling of pancreatic neuroendocrine tumors (pNETS) and the clinical potential.
Camilli M; Papadimitriou K; Nogueira A; Incorvaia L; Galvano A; D'Antonio F; Ferri J; Santini D; Silvestris N; Russo A; Peeters M; Rolfo C
Expert Rev Gastroenterol Hepatol; 2018 May; 12(5):471-478. PubMed ID: 29629846
[TBL] [Abstract][Full Text] [Related]
12. Biomarkers and pathways of chemoresistance and chemosensitivity for personalized treatment of pancreatic adenocarcinoma.
Zemanek T; Melichar B; Lovecek M; Soucek P; Mohelnikova-Duchonova B
Pharmacogenomics; 2019 Jan; 20(2):113-127. PubMed ID: 30539680
[TBL] [Abstract][Full Text] [Related]
13. Pancreatic cancer subtypes: a roadmap for precision medicine.
Torres C; Grippo PJ
Ann Med; 2018 Jun; 50(4):277-287. PubMed ID: 29537309
[TBL] [Abstract][Full Text] [Related]
14. Personalising pancreas cancer treatment: When tissue is the issue.
Sjoquist KM; Chin VT; Chantrill LA; O'Connor C; Hemmings C; Chang DK; Chou A; Pajic M; Johns AL; Nagrial AM; Biankin AV; Yip D
World J Gastroenterol; 2014 Jun; 20(24):7849-63. PubMed ID: 24976722
[TBL] [Abstract][Full Text] [Related]
15. Genomics of pancreatic ductal adenocarcinoma.
Pilarsky C; Grutzmann R
Hepatobiliary Pancreat Dis Int; 2014 Aug; 13(4):381-5. PubMed ID: 25100122
[TBL] [Abstract][Full Text] [Related]
16. Genomic instability in pancreatic adenocarcinoma: a new step towards precision medicine and novel therapeutic approaches.
Sahin IH; Lowery MA; Stadler ZK; Salo-Mullen E; Iacobuzio-Donahue CA; Kelsen DP; O'Reilly EM
Expert Rev Gastroenterol Hepatol; 2016 Aug; 10(8):893-905. PubMed ID: 26881472
[TBL] [Abstract][Full Text] [Related]
17. The underlying mechanisms of non-coding RNAs in the chemoresistance of pancreatic cancer.
Xiong G; Feng M; Yang G; Zheng S; Song X; Cao Z; You L; Zheng L; Hu Y; Zhang T; Zhao Y
Cancer Lett; 2017 Jul; 397():94-102. PubMed ID: 28254409
[TBL] [Abstract][Full Text] [Related]
18. Using Somatic Mutations to Guide Treatment Decisions: Context Matters.
Horlings HM; Shah SP; Huntsman DG
JAMA Oncol; 2015 Jun; 1(3):275-6. PubMed ID: 26181166
[No Abstract] [Full Text] [Related]
19. Precision and predictive medicine in urothelial cancer: are we making progress?
Bellmunt J; Orsola A; Sonpavde G
Eur Urol; 2015 Oct; 68(4):547-9. PubMed ID: 25935702
[TBL] [Abstract][Full Text] [Related]
20. Integrated genomic and transcriptomic analysis of human brain metastases identifies alterations of potential clinical significance.
Saunus JM; Quinn MC; Patch AM; Pearson JV; Bailey PJ; Nones K; McCart Reed AE; Miller D; Wilson PJ; Al-Ejeh F; Mariasegaram M; Lau Q; Withers T; Jeffree RL; Reid LE; Da Silva L; Matsika A; Niland CM; Cummings MC; Bruxner TJ; Christ AN; Harliwong I; Idrisoglu S; Manning S; Nourse C; Nourbakhsh E; Wani S; Anderson MJ; Fink JL; Holmes O; Kazakoff S; Leonard C; Newell F; Taylor D; Waddell N; Wood S; Xu Q; Kassahn KS; Narayanan V; Taib NA; Teo SH; Chow YP; kConFab ; Jat PS; Brandner S; Flanagan AM; Khanna KK; Chenevix-Trench G; Grimmond SM; Simpson PT; Waddell N; Lakhani SR
J Pathol; 2015 Nov; 237(3):363-78. PubMed ID: 26172396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
